1. HBW Insight
  2. >>Leadership

Unilever Announces Corporate Restructuring Amid Reports Of Activist Investor Influence

 
• By Eileen Francis

Around 1,500 senior and junior management roles will be cut under Unilever’s announced plan to reshape its corporate matrix, the firm reports on 25 January. The news comes a day after reports that activist investor Nelson Peltz of Trian Fund Management has taken a stake in the business.

Unilever Building

Still nursing its wounds after a failed bid for GlaxoSmithKline Consumer Healthcare and possibly facing activist investor pressure, Unilever PLC plans to reshape its corporate matrix into a leaner team organized around five distinct business groups.

Those groups are Beauty & Wellbeing, Personal Care, Home Care, Nutrition and Ice Cream, each “fully responsible and accountable for their strategy, growth, and profit delivery globally,”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By David Ridley

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

Makary’s Reorganization Decision A Turning Point For US FDA?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel

 
• By Sue Sutter and Derrick Gingery

Alonza Cruse, director of the Office of Human and Animal Drugs Inspectorate, and two other senior inspection officials are departing, along with Mark Raza, chief counsel from 2021 until January.

More from HBW Insight

Looming Tariffs Give Boost To Latest PCH Results While Cutting Costs In Response Takes Priority

 
• By Malcolm Spicer

Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.

Haleon Utilizing AI To Develop Natural CHC Products

 
• By Tom Gallen

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 
• By Malcolm Spicer

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.